Pneumologie (Stuttgart, Germany)最新文献_第4页

[From the clinic to the private practice]. [从诊所到私人诊所]。

IF 1.7

Pneumologie (Stuttgart, Germany) Pub Date : 2026-08-01 Epub Date: 2026-01-26 DOI: 10.1055/a-2790-7521

Norbert Mülleneisen, Robin Engert

引用次数: 0

[From vibration trauma to disturbed sensorimotor function: The beginning of a vicious circle in obstructive sleep apnea (OSA)?] 从振动创伤到感觉运动功能紊乱：阻塞性睡眠呼吸暂停（OSA）恶性循环的开始？]

IF 1.7

Pneumologie (Stuttgart, Germany) Pub Date : 2026-08-01 Epub Date: 2026-01-26 DOI: 10.1055/a-2780-2478

Ulrich Koehler, Olaf Hildebrandt, Mikail Aykut Degerli, Christian Viniol, Wulf Hildebrandt, Katrin Roth, Laura Gartmann, Regina Conradt, Janine Sambale, Heike Korbmacher-Steiner, Gernot Rohde

引用次数: 0

[Tuberculous mastitis: A rare manifestation of extrapulmonary tuberculosis]. 结核性乳腺炎：肺外结核的一种罕见表现。

IF 1.7

Pneumologie (Stuttgart, Germany) Pub Date : 2026-08-01 Epub Date: 2026-04-27 DOI: 10.1055/a-2845-3440

Friederike Dellbrügge, Nora Schaumann, Marcus Kruppa, Hendrik Suhling, Franz Christoph Bange, Felix C Ringshausen

引用次数: 0

[Correction: Comparative analysis of drug therapy for fibrotic interstitial lung diseases based on results of phase 3 trials]. [更正：基于3期试验结果的纤维化间质性肺疾病药物治疗对比分析]。

IF 1.7

Pneumologie (Stuttgart, Germany) Pub Date : 2026-07-15 DOI: 10.1055/a-2915-1925

Dirk Koschel, Jürgen Behr, Francesco Bonella

引用次数: 0

Outcomes and risk factors for mortality in patients with pulmonary non-tuberculous mycobacterial infections: A single-center retrospective cohort study. 肺非结核分枝杆菌感染患者死亡的结局和危险因素：一项单中心回顾性队列研究

IF 1.7

Pneumologie (Stuttgart, Germany) Pub Date : 2026-07-07 DOI: 10.1055/a-2877-8192

Zsolt Gurabi, Markus Zenner, Wilhelmina van den Dool, Martin Hetzel, Adrian Gillissen

{"title":"Outcomes and risk factors for mortality in patients with pulmonary non-tuberculous mycobacterial infections: A single-center retrospective cohort study.","authors":"Zsolt Gurabi, Markus Zenner, Wilhelmina van den Dool, Martin Hetzel, Adrian Gillissen","doi":"10.1055/a-2877-8192","DOIUrl":"https://doi.org/10.1055/a-2877-8192","url":null,"abstract":"Abstract: This study evaluates 5-year survival in patients with non-tuberculous mycobacterial pulmonary disease and examines the impact of risk factors, including comorbidities, patient characteristics and different mycobacterial species.We retrospectively analyzed comorbidities, patient characteristics, microbiological and radiological findings of adult patients hospitalized with non-tuberculous mycobacterial pulmonary disease at the Red Cross Hospital Bad Cannstatt, Stuttgart, Germany, between 2005 and 2019. Depending on the presence or absence of comorbidities and various risk factors, patients were grouped, and their 5-year survival following the initial diagnosis of nontuberculous mycobacterial pulmonary disease was compared. In addition, independent covariates were simultaneously analyzed to assess whether they were significantly associated with an increased risk of mortality.In this cohort of 52 patients (mean age 64.2±12.2 years) with non-tuberculous mycobacterial pulmonary disease, the 5-year survival rate was 55.8%. Five-year survival was markedly lower among individuals with coexisting chronic obstructive pulmonary disease or heart failure as well as in those without culture conversion. In a multivariate Cox regression analysis of independent covariates, age and increasing Charlson Comorbidity Index scores were associated with reduced 5-year survival.A 5-year survival rate of less than 60% indicates a poor prognosis in patients with non-tuberculous mycobacterial pulmonary disease, highlighting the need for more effective management of both the disease and associated comorbidities.","PeriodicalId":520755,"journal":{"name":"Pneumologie (Stuttgart, Germany)","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148407876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[ROSE using Van Gogh microscopy in interventional pulmonology]. [ROSE在介入肺病学中的应用]。

IF 1.7

Pneumologie (Stuttgart, Germany) Pub Date : 2026-07-07 DOI: 10.1055/a-2890-1603

Björn Schwick, José Miguel Sodi Luna

引用次数: 0

["PneumoNEXT - Continuing Education, Exchange, The Future": A pilot project to support the next generation of pulmonologists]. [“PneumoNEXT -继续教育，交流，未来”：支持下一代肺科医生的试点项目]。

IF 1.7

Pneumologie (Stuttgart, Germany) Pub Date : 2026-07-07 DOI: 10.1055/a-2879-8785

Marc Alexander Birner, Sebastian M K Schickinger, Daniela Gompelmann, Matthias Welsner, Mathias M Borst, Julia Wälscher, Christoph Fisser

{"title":"[\"PneumoNEXT - Continuing Education, Exchange, The Future\": A pilot project to support the next generation of pulmonologists].","authors":"Marc Alexander Birner, Sebastian M K Schickinger, Daniela Gompelmann, Matthias Welsner, Mathias M Borst, Julia Wälscher, Christoph Fisser","doi":"10.1055/a-2879-8785","DOIUrl":"https://doi.org/10.1055/a-2879-8785","url":null,"abstract":"Abstract: Attracting and retaining the next generation of physicians for a medical specialty is discussed in many fields of medicine as one of the key issues for the future. This question is particularly relevant for pulmonology, given the growing importance of respiratory diseases, which are often given only secondary importance in university curricula. For this reason, the event \"PneumoNEXT - Continuing Education, Exchange, Future\" was conceived as a one-week continuing education program for medical students starting in their 10th semester and physicians in training. The program combines case-based learning with practical workshops on key topics in pulmonology, as well as opportunities for networking and exchange with experienced pulmonologists.The pilot project included 16 participants (mean age 33 ± 5.9 years, 50% women). In the accompanying evaluation via an online survey, all participants reported a positive change in their confidence in practical decision-making. Additionally, 93% stated that their professional focus had shifted more toward pulmonology and that they would like to begin or continue pulmonology training. There is still potential for improvement, including the integration of patient-centered workshop formats. PneumoNEXT can therefore be understood as a practice-oriented, structured continuing education and networking format that creates suitable conditions to promote interest in pulmonology, introduce young professionals to the field at an early stage, and support the decision to pursue further training in pulmonology.","PeriodicalId":520755,"journal":{"name":"Pneumologie (Stuttgart, Germany)","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148407924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Catamenial pneumothorax complicated by massive right diaphragmatic hernia with solid organ herniation. 双膜性气胸合并大块右侧膈疝合并实性器官疝。

IF 1.7

Pneumologie (Stuttgart, Germany) Pub Date : 2026-07-06 DOI: 10.1055/a-2882-7406

Supakorn Srihattapadungkit, Klein Dantis, Jakraphan Yu, Sira Laohathai

引用次数: 0

[Comparative analysis of drug therapy for fibrotic interstitial lung diseases based on results of phase 3 trials]. [基于3期研究结果的纤维化间质性肺疾病药物治疗对比分析]。

IF 1.7

Pneumologie (Stuttgart, Germany) Pub Date : 2026-07-06 DOI: 10.1055/a-2883-1874

Dirk Koschel, Jürgen Behr, Francesco Bonella

{"title":"[Comparative analysis of drug therapy for fibrotic interstitial lung diseases based on results of phase 3 trials].","authors":"Dirk Koschel, Jürgen Behr, Francesco Bonella","doi":"10.1055/a-2883-1874","DOIUrl":"10.1055/a-2883-1874","url":null,"abstract":"Background: Idiopathic pulmonary fibrosis (IPF) and other progressive pulmonary fibrosis (PPF) forms are associated with significant morbidity and mortality. Pirfenidone and nintedanib are the currently approved antifibrotic drugs in Germany. Based on the positive results of both Phase-3 trials FIBRONEER-IPF and FIBRONEER-ILD, the phosphodiesterase-4B inhibitor nerandomilast was approved in 2025 for the treatment of IPF in USA, but not yet in Germany.Materials and methods: We performed a comparative analysis of the results of phase 3 randomized clinical trials of pirfenidone, nintedanib and nerandomilast regarding patient characteristics, efficacy and safety.Results: Eight phase 3 trials were included: 3 with pirfenidone, 3 with nintedanib, und 2 with nerandomilast. The characteristics of the trials' populations showed substantial differences. In terms of the primary endpoint reduction of FVC decline over one year, all the three compounds demonstrated similar efficacy. Secondary endpoints across the trials were heterogeneous, and no positive efficacy for patient-reported outcomes was observed for any of the three drugs. The best tolerability and safety profile was demonstrated for nerandomilast.Conclusion: In the near future, nerandomilast could become the third available antifibrotic drug in Germany for the treatment of IPF and PPF, showing a similar efficacy profile to pirfenidone and nintedanib, with a better tolerability. The different trials populations should be considered when comparing the clinical trials results. New guidelines are mandatory to unravel the role of nerandomilast in the treatment algorithm of IPF and PPF.","PeriodicalId":520755,"journal":{"name":"Pneumologie (Stuttgart, Germany)","volume":" ","pages":""},"PeriodicalIF":1.7,"publicationDate":"2026-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148400442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

[Acute lung failure]. [急性肺衰竭]。

IF 1.7

Pneumologie (Stuttgart, Germany) Pub Date : 2026-07-01 Epub Date: 2026-06-02 DOI: 10.1055/a-2867-9658

Ulrike Olgemöller, Christian Becker, Lars-Olav Harnisch

{"title":"[Acute lung failure].","authors":"Ulrike Olgemöller, Christian Becker, Lars-Olav Harnisch","doi":"10.1055/a-2867-9658","DOIUrl":"10.1055/a-2867-9658","url":null,"abstract":"Abstract: Acute respiratory distress syndrome (ARDS) represents one of the most complex clinical entities in intensive care medicine and confronts clinicians with novel challenges daily due to its heterogeneity. With a mortality rate of 35-45%, it remains a significant clinical challenge; however, current developments offer promising therapeutic options.Contemporary ARDS management continues to evolve: parameters such as driving pressure and mechanical power complement established lung-protective ventilation concepts and enable more precise therapeutic control. Transpulmonary pressure measurement supports individualized PEEP titration, while automated closed-loop systems can significantly extend time within lung-protective ranges.Veno-venous extracorporeal membrane oxygenation (VV-ECMO) has established itself as an important rescue therapy and received conditional recommendation for the first time in the new S3 guideline 2025. Ultra-protective ventilation strategies under ECMO enable substantial reduction of mechanical stress and support the concept of \"lung rest\".From epidemiology and pathophysiology to novel disease entities such as EVALI and innovative monitoring procedures, this review article provides a current overview of the syndrome's fundamentals as well as modern diagnostics and therapy of ARDS, and demonstrates how these insights can be beneficially implemented in daily clinical practice.","PeriodicalId":520755,"journal":{"name":"Pneumologie (Stuttgart, Germany)","volume":" ","pages":"500-513"},"PeriodicalIF":1.7,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148152996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0